北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場、製品タイプ別 (消耗品、機器、ソフトウェア)、テクノロジー別 (DNA 蛍光 in situ ハイブリダイゼーション、RNA 蛍光 in situ ハイブリダイゼーション、PNA 蛍光 in situ ハイブリダイゼーション、その他)、アプリケーション別 (がん研究、遺伝子研究、感染症、個別化医療、その他)、使用法別 (臨床、研究、コンパニオン診断)、エンドユーザー別 (病院・診療所、診断研究所、製薬・バイオテクノロジー企業、契約研究機関、学術・研究機関、その他)、流通チャネル別 (小売販売、直接入札、オンライン販売、その他) - 2030 年までの業界動向と予測。
北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場の分析と洞察
がんや遺伝性疾患に関する一般の認識の高まりにより、市場の需要が高まっています。主要な市場プレーヤーは、この重要な時期にさまざまな製品の発売と承認に注力しています。さらに、FISH の改良された高度な手順の増加も、市場の需要の高まりに貢献しています。
北米の蛍光in situハイブリダイゼーション（FISH）市場は、がんやその他の慢性疾患の増加により、2023年から2030年の予測期間に成長すると予想されています。政府やその他の団体による研究活動への多額の資金提供も、市場の成長を牽引すると予想されています。これに伴い、メーカーは市場に新製品を投入するための研究開発活動に取り組んでいます。ただし、治療手順におけるFISH技術の高コストは、市場の成長を抑制すると予想されます。特定のバイオマーカーとさまざまなプローブの需要の増加は、治療を強化するための市場成長の機会を提供すると予想されます。遺伝性疾患に対するより質の高いヘルスケアの需要の高まりと、個別化医療の採用の増加は、市場の成長を後押しすると予想されます。ただし、FISH技術に関連する倫理的な懸念と、熟練した認定専門家の不足は、市場の成長に課題をもたらすと予想されます。
Data Bridge Market Research の分析によると、北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場は、予測期間中に 8.7% の CAGR で成長し、2030 年までに 8 億 3,241 万米ドルに達する見込みです。乳がんや遺伝性疾患の患者数が増加しているため、製品タイプ セグメントが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021（2015～2020年にカスタマイズ可能） |
|
定量単位 |
収益は百万米ドル、価格は米ドル |
|
対象セグメント |
製品タイプ別（消耗品、機器、ソフトウェア）、技術別（DNA蛍光in situハイブリダイゼーション、RNA蛍光in situハイブリダイゼーション、PNA蛍光in situハイブリダイゼーション、その他）、用途別（がん研究、遺伝子研究、感染症、個別化医療、その他）、使用法別（臨床、研究、コンパニオン診断）、エンドユーザー別（病院・診療所、診断研究所、製薬・バイオテクノロジー企業、契約研究機関、学術・研究機関、その他）、流通チャネル別（小売販売、直接入札、オンライン販売、その他） |
|
対象国 |
米国、カナダ、メキシコ |
|
対象となる市場プレーヤー |
Thermo Fisher Scientific Inc.、Bio-Techne、Abbott、Agilent Technologies、Merck KGaA、F. Hoffmann-La Roche Ltd、Abnova Corporation、BioDot、Biocare Medical、LLC、Abcam plc、Sysmex Asia Pacific Pte Ltd（Sysmex Corporationの子会社）、BIOZOL Diagnostics Vertrieb GmbH、Zytomed Systems GmbH、Genemed Biotechnologies、Inc.、Bio SB、BioGenex、Excilone、MetaSystems、Kaneka Eurogentec SA、BioCat GmbH、Leica Biosystems Nussloch GmbHなど |
市場の定義
蛍光 in situ ハイブリダイゼーション (FISH) と呼ばれる分子細胞遺伝学的手法により、細胞内の特定の DNA 配列または染色体全体の位置を特定できます。この手法は、遺伝性疾患の診断、遺伝子のマッピング、染色体異常の特定に使用され、また、関連種の異なる染色体上の遺伝子がどのように構成されているかを比較するためにも使用できます。FISH を実行すると、二重らせん構造がほどかれ、蛍光分子に接続されたすべてのプローブが、蛍光顕微鏡で確認できるサンプル DNA の特定の配列に結合されます。
FISH は、腫瘍学、予防および生殖医療、ゲノムおよび細胞生物学研究の診断目的で頻繁に使用されています。これは、感染症や染色体異常を発見するための業界で認められた方法です。ただし、FISH 製品およびプローブの承認に関する厳格な規制と基準により、市場の成長が抑制されると予想されます。
北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 遺伝性疾患とがんの負担が増大
遺伝子異常は全体としてはまれですが、個々の病気としては非常に頻繁に発生します。遺伝子の変化はすべてのがんの原因です。がんのわずか 5% から 10% が遺伝的に素因があります。それでも、家族内で同じ種類のがんが発生する場合、遺伝ががんの原因であるように見えることがあります。血液がんと固形がんはどちらも、さまざまな遺伝子異常を伴う異質な疾患です。過去 20 年間に実施されたゲノム不安定性と疾患発症の関係に関する広範な調査の結果、染色体断片の増加、喪失、または再配置や遺伝子変異などのゲノム異常が増加しており、さまざまな悪性腫瘍の発症の原動力となっています。欠失、重複、転座などのさまざまな染色体異常の臨床診断は、FISH やその他の in situ ハイブリダイゼーション技術に依存しており、これが市場の成長を牽引しています。
- FISH製品の革新と進歩
特定の DNA 配列を見つけ、遺伝性疾患を診断し、遺伝子をマッピングし、さまざまな癌を引き起こす新しい癌遺伝子または遺伝子異常を発見するための最も信頼性の高い方法は FISH です。最近の技術の進歩により、比較ゲノムハイブリダイゼーションやマルチカラー全染色体プローブを使用したマルチプレックス FISH などのアレイベースの方法を使用して、ゲノム全体を同時にスクリーニングすることが可能になりました。遺伝性疾患との戦いにおいて、FISH は細胞遺伝学の分野を根本的に変革し、現在では市場の成長を促進する信頼できる診断および研究ツールとして認められています。
拘束
- FISH検査の高コスト
FISH として知られる高分子認識技術は、DNA または DNA/RNA 二重鎖の相補性に依存しています。FISH テストは、特定の遺伝子または遺伝子セグメントを含む、人間の細胞に存在する遺伝物質を「マッピング」します。FISH テストは、病気に関連する遺伝子異常を見つけることができるため、一部の種類の癌の診断に役立ちます。コストの問題は、現代の分子診断ラボにとって最も重要な問題です。ラボが増加するテスト量とスループットを処理できるようになるだけでなく、複雑な分子アッセイの自動化により、市場の成長を抑制する試薬費用の観点からテストのコストが大幅に削減されます。
機会
- 遺伝子異常の早期発見に関する国民の意識の高まり
遺伝子検査は、遺伝性疾患の予防、治療、早期発見において患者が重要な決定を下すのに役立ちます。遺伝子検査の重要性に対する認識が低いことが、遺伝性疾患の発生率の増加につながっています。
遺伝性疾患は、通常 DNA の変異、または染色体の数や全体的な構造の変化によって引き起こされる、人に受け継がれる健康状態です。よく知られているいくつかの種類の疾患は、遺伝性遺伝子変異に関連していることが判明しています。
Henceforth, the rising awareness about the early detection of genetic disorders using the FISH technique helps in the diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers and genetic disorders, which provides the opportunity for market growth.
Challenge
- Stringent Government Regulations for the Approval of FISH Probes
The use of FISH techniques across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases, which are preventable by early diagnosis and timely treatments. At the same time, the players of the FISH technology in the market have to follow certain regulations to get approval from the upper authorities for launching the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks of all the steps. The pre-market approval of various medical devices varies from one country to another.
Post-COVID-19 Impact on North America Fluorescent in Situ Hybridization (FISH) Market
The pandemic has had adverse impacts on the FISH manufacturers as well as users. The market has been significantly influenced by COVID-19, which has led to an increase in research studies utilizing FISH. One such study, published in November 2022 in the PLOS One Journal, employed a FISH-based method to detect SARS-CoV-2 in saliva. The method involved using a Cy3-labeled DNA probe specific to SARS-CoV-2, and the analysis was carried out manually using fluorescence microscopy as a proof-of-concept.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the FISH market.
Recent Developments
- In March 2023, Abcam plc. announced that it has received "Antibody Supplier of the Year" in CiteAb's distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb's "Antibody Supplier of the Year" honor. Moreover, Abcam plc. was given a "highly commended" rating in the category of "Post Translational Modification Antibody Supplier of the Year," recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a North America scale
- In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the North America market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers
- In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world
North America Fluorescent in Situ Hybridization (FISH) Market Scope
North America Fluorescent in Situ Hybridization (FISH) market is segmented into six notable segments based on product type, technology, application, usage, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY PRODUCT TYPE
- CONSUMABLES
- INSTRUMENT
- SOFTWARE
Based on product type, the market is segmented into consumables, instrument, and software.
BY TECHNOLOGY
- DNA FLUORESCENT IN SITU HYBRIDIZATION
- RNA FLUORESCENT IN SITU HYBRIDIZATION
- PNA FLUORESCENT IN SITU HYBRIDIZATION
- OTHERS
Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.
BY APPLICATION
- CANCER RESEARCH
- GENETIC RESEARCH
- INFECTIOUS DISEASE
- PERSONALIZED MEDICINE
- OTHER
Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.
BY USAGE
- CLINICAL
- RESEARCH
- COMPANION DIAGNOSTIC
Based on usage, the market is segmented into clinical, research, and companion diagnostic.
BY END USER
- HOSPITALS & CLINICS
- DIAGNOSTIC LABORATORIES
- PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES
- CONTRACT RESEARCH ORGANISATIONS
- ACADEMIC & RESEARCH ORGANISATIONS
- OTHERS
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others.
BY DISTRIBUTION CHANNEL
- RETAIL SALES
- DIRECT TENDER
- ONLINE SALES
- OTHERS
Based on distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.
North America Fluorescent in Situ Hybridization (FISH) Market Regional Analysis/Insights
北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場が分析され、製品タイプ、テクノロジー、アプリケーション、使用法、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。
この市場レポートで取り上げられている国は、米国、カナダ、メキシコです。
米国は、高いGDPを誇る最大の消費者市場に主要な市場プレーヤーが存在し、FISH市場における最新の高度な技術と発明を有していることから、北米地域を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、北米ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
競争環境と北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場シェア分析
北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、および技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、会社の市場への重点にのみ関連しています。
北米の蛍光 in situ ハイブリダイゼーション (FISH) 市場で活動している主要な市場プレーヤーには、Thermo Fisher Scientific Inc.、Bio-Techne、Abbott、Agilent Technologies, Inc.、Merck KGaA、F. Hoffmann-La Roche Ltd、Abnova Corporation、BioDot、Biocare Medical, LLC、Abcam plc.、Sysmex Asia Pacific Pte Ltd (Sysmex Corporation の子会社)、BIOZOL Diagnostics Vertrieb GmbH、Zytomed Systems GmbH、Genemed Biotechnologies, Inc.、Bio SB、BioGenex、Excilone、MetaSystems、Kaneka Eurogentec SA、BioCat GmbH、Leica Biosystems Nussloch GmbH などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
4.4 CONCLUSION
5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES
6.2 RESTRAINTS
6.2.1 HIGH COST OF FISH TESTING
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY
7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 FISH PROBE
7.2.1.1 FISH PROBE, BY PROBE TYPE
7.2.1.1.1 CHROMOSOME FISH PROBE
7.2.1.1.2 SPLIT FISH PROBES
7.2.1.1.3 TRANSLOCATION FISH PROBES
7.2.1.1.4 SUBTELOMERE FISH PROBES
7.2.1.1.5 PRENATAL FISH PROBES
7.2.1.1.6 OTHERS PROBES
7.2.1.2 FISH PROBE, BY TECHNOLOGY
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.2 C-ISH
7.2.1.2.3 D-ISH
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.5 OTHERS
7.2.1.3 FISH PROBE, BY TYPE
7.2.1.3.1 RNA
7.2.1.3.1.1 MRNA
7.2.1.3.1.2 MIRNA
7.2.1.3.1.3 OTHERS
7.2.1.3.2 DNA
7.2.2 ACCESSORY KITS & REAGENTS
7.2.2.1 KITS
7.2.2.2 BUFFER
7.2.2.3 DYES
7.2.2.4 OTHERS
7.3 INSTRUMENT
7.3.1 STANDALONE
7.3.2 PORTABLE
7.3.3 HANDHELD
7.4 SOFTWARE
8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION
8.5 OTHERS
9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER RESEARCH
9.2.1 CANCER RESEARCH, BY CANCER TYPE
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS)
9.2.1.1.1 BREAST CANCER
9.2.1.1.2 LUNG CANCER
9.2.1.1.3 MELANOMA
9.2.1.1.4 PROSTRATE CANCER
9.2.1.1.5 OVARIAN CANCER
9.2.1.1.6 OTHERS
9.2.1.2 HEMATOPOETIC MALIGNANCIES
9.2.1.2.1 LEUKEMIA
9.2.1.2.2 MULTIPLE MYELOMA
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS)
9.2.2 CANCER RESEARCH, BY PRODUCT
9.2.2.1 CONSUMABLES
9.2.2.2 INSTRUMENTS
9.2.2.3 SOFTWARE
9.3 GENETIC RESEARCH
9.3.1 CYTOGENETICS
9.3.2 CHROMOSOMAL ABNORMALITIES
9.3.3 OTHERS
9.4 INFECTIOUS DISEASE
9.4.1 CONSUMABLES
9.4.2 INSTRUMENTS
9.4.3 SOFTWARE
9.5 PERSONALIZED MEDICINE
9.6 OTHERS
10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE
10.1 OVERVIEW
10.2 RESEARCH
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 SOFTWARE
10.3 CLINICAL
10.3.1 CONSUMABLES
10.3.2 INSTRUMENT
10.3.3 SOFTWARE
10.4 COMPANION DIAGNOSTIC
10.4.1 CONSUMABLES
10.4.2 INSTRUMENT
10.4.3 SOFTWARE
11 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER
11.1 OVERVIEW
11.2 DIAGNOSTIC LABORATORIES
11.3 HOSPITALS & CLINICS
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 CONTRACT RESEARCH ORGANIZATIONS
11.7 OTHERS
12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.3 ONLINE SALES
12.4 DIRECT TENDER
12.5 OTHERS
13 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MERCK KGAA
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 AGILENT TECHNOLOGIES, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 F. HOFFMANN-LA ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 THERMO FISCHER SCIENTIFIC INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABCAM PLC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 COMPANY SHARE ANALYSIS
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPMENTS
16.7 ABNOVA CORPORATION
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIO SB
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOCARE MEDICAL, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BIOCAT GMBH
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIODOT
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 BIOGENEX
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 BIO-TECHNE
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 COMPANY SHARE ANALYSIS
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPMENT
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 EXCILONE
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 GENEMED BIOTECHNOLOGIES, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 KANEKA EUROGENTEC S.A.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 METASYSTEMS
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 ZYTOMED SYSTEMS GMBH
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 80 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 U.S. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 82 U.S. NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 83 U.S. HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 84 U.S. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 U.S. GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 U.S. INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 88 U.S. RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 89 U.S. CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 90 U.S. COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 91 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 CANADA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 96 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 97 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 CANADA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 102 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 CANADA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 104 CANADA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 CANADA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 CANADA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 CANADA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 CANADA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 110 CANADA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 111 CANADA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 112 CANADA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 113 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 115 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 119 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 MEXICO ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 MEXICO INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 MEXICO CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 126 MEXICO NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 127 MEXICO HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 128 MEXICO CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 MEXICO GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 130 MEXICO INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 131 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 132 MEXICO RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 133 MEXICO CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 134 MEXICO COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 135 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 136 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
FIGURE 14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022
FIGURE 19 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022
FIGURE 23 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022
FIGURE 27 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022
FIGURE 31 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022)
FIGURE 39 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022)
FIGURE 40 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
